About Nissor Pharmaceuticals
Nissor Pharmaceuticals is a Healthcare company. Research and development in bio-therapeutics, cosmetology, and herbal products in India. It operates in the Healthcare and Consumer sectors. Its Indian entity Nissor Pharmaceuticals Limited reported revenue of ₹1.20 Cr. Nissor Pharmaceuticals offers products and services including Nisglow and Immusor. Its focus areas include Pharmaceuticals, Bio-therapeutics, Plasma Proteins and Biosimilars and Novel Proteins.
Company details
Nissor Pharmaceuticals is recognized as a research-driven entity that develops opportunities in bio-therapeutics, including plasma proteins and biosimilars, as well as cosmetology and herbal products. One of the first L-Glutathione products in India, Nisglow, was launched by the company, alongside growing brands like Albusor and Immusor in the plasma proteins sector. A global presence is maintained in countries such as UAE, USA, and UK, with a team composed of professionals including Ph.Ds and M.Ds. In-house capabilities cover research, clinical development, and manufacturing, while advancements have been made in herbal sectors like Lustgra for male health applications.
- SectorsHealthcareConsumer
- Email••••••••
- Phone•••• ••••
- Legal Name Nissor Pharmaceuticals Ltd
- Date of Incorporation 08 May, 2015
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹1.20 Cr
FY 2025 · -52% YoY
- Indian entity net loss-₹13.1 Lakh
FY 2025 · -11% margin
- Indian entity EBITDA-₹6.2 Lakh
FY 2025 · -5% margin
Associated legal entities of Nissor Pharmaceuticals
Nissor Pharmaceuticals operates through Nissor Pharmaceuticals Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Nissor Pharmaceuticals Limited CIN U74900MH2015PLC264184 | Active | 08 May 2015 | Mumbai, Maharashtra | ₹1.2 Cr | 4 | View details |
Products & Services of Nissor Pharmaceuticals
Nissor Pharmaceuticals offers a comprehensive portfolio of products and services, including Nisglow and Immusor.
L-Glutathione products are offered for skin care purposes
Plasma proteins are provided under this brand for therapeutic uses
Board of directors of Nissor Pharmaceuticals Limited (Nissor Pharmaceuticals)
Nissor Pharmaceuticals Limited is the primary company behind Nissor Pharmaceuticals. The board of Nissor Pharmaceuticals Limited currently have 4 directors; the longest-serving is Manish Pitambar Satia, appointed in 2015. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manish Pitambar Satia DIN 02332443 | Director | 08 May 2015 | 11 yrs 5 mo | Nissor Pharmaceuticals Limited |
| Jeet Jain Champalal DIN 02333174 | Director | 08 May 2015 | 11 yrs 5 mo | Nissor Pharmaceuticals Limited |
| Vansh Hasmukh Jain DIN 08376792 | Director | 01 Mar 2019 | 7 yrs 7 mo | Nissor Pharmaceuticals Limited |
| Berkha Pitamber Satia DIN 08827065 | Director | 10 Aug 2020 | 6 yrs 2 mo | Nissor Pharmaceuticals Limited |
Financials of Nissor Pharmaceuticals
Figures of Nissor Pharmaceuticals Limited, the primary company behind Nissor Pharmaceuticals, for FY 2025. Revenue was ₹1.20 Cr (-52% year on year). Net loss was -₹13.1 Lakh (-11% margin). EBITDA was -₹6.2 Lakh (-5% margin). Revenue has grown at a compounded annual rate of -19% over three years and -31% over five years.
- ₹1.20 CrRevenue · FY 2025 · -52% YoY
- -₹13.1 LakhNet loss · -11% margin
- -₹6.2 LakhEBITDA · -5% margin
- ₹5 LakhPaid-up capital
- -19%Revenue CAGR, 3 years
- -31%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Nissor Pharmaceuticals Limited are on its company page.
Detailed financial statements for Nissor Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nissor Pharmaceuticals
The primary company behind Nissor Pharmaceuticals, Nissor Pharmaceuticals Limited, reported revenue of ₹1.20 Cr for FY 2025, down 52% year on year.
Nissor Pharmaceuticals is recognized as a research-driven entity that develops opportunities in bio-therapeutics, including plasma proteins and biosimilars, as well as cosmetology and herbal products. One of the first L-Glutathione products in India, Nisglow, was launched by the company, alongside growing brands like Albusor and Immusor in the plasma proteins sector. A global presence is maintained in countries such as UAE, USA, and UK, with a team composed of professionals including Ph.Ds and M.Ds. In-house capabilities cover research, clinical development, and manufacturing, while advancements have been made in herbal sectors like Lustgra for male health applications.
Nissor Pharmaceuticals offers Nisglow and Immusor.
Nissor Pharmaceuticals operates through Nissor Pharmaceuticals Limited.
The legal entities of Nissor Pharmaceuticals currently have 4 directors, including Manish Pitambar Satia, Berkha Pitamber Satia, Vansh Hasmukh Jain and others.